Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Xeloda “Reminder” Ad Cited By FDA For Reference to Oral Delivery

Executive Summary

Roche's use of the phrase "oral chemotherapy" in a direct-to-consumer "reminder" ad makes the ad product-specific for Xeloda, FDA said in a Jan. 9 letter

You may also be interested in...



FDA Warns Roche On Xeloda Promotion; Agency Is Keeping Close Eye On Drug

FDA is directing Roche to conduct a broad corrective campaign for the chemotherapy agent Xeloda (capecitabine)

FDA Warns Roche On Xeloda Promotion; Agency Is Keeping Close Eye On Drug

FDA is directing Roche to conduct a broad corrective campaign for the chemotherapy agent Xeloda (capecitabine)

FDA Advertising Letters, In Brief

Cialis web promotions: A Jan. 3 letter from FDA Division of Drug Marketing, Advertising & Communications objects to websites promoting the safety and efficacy of Lilly/Icos' unapproved erectile dysfunction product Cialis (tadalafil), including statements that Cialis enables "a man with ED to engage in intercourse within a 24-hour window" and "regain spontaneity;" that data suggests "dosing for Cialis should be simple and uncomplicated" and that "Cialis was well-tolerated, with generally mild-to-moderate side effects that diminished in frequency with continued treatment." Lilly said the companies will remove the identified items...

UsernamePublicRestriction

Register

PS039386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel